Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Recruiting 4

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Gynecologic 4Genitourinary 2Gastrointestinal 2Thoracic 1Sarcoma 1Head & Neck 1Dermatologic 1CNS 1Breast 1

Conditions

Breast Neoplasms 71Neoplasm Metastasis 26Stomach Neoplasms 12Carcinoma, Non-Small-Cell Lung 11Colorectal Neoplasms 10Neoplasms 8Brain Neoplasms 8Adenocarcinoma 6Triple Negative Breast Neoplasms 5Pancreatic Neoplasms 4Ovarian Neoplasms 4Esophageal Neoplasms 4Endometrial Neoplasms 4Salivary Gland Neoplasms 3Recurrence 3HER2-positive Breast Cancer 3Advanced Solid Tumor 3Sarcoma 2Prostatic Neoplasms 2Neoplasm, Residual 2Meningeal Carcinomatosis 2Melanoma 2HER2-positive Gastric Cancer 2Gastrointestinal Neoplasms 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Breast Cancer With Brain Metastasis 2Advanced Breast Cancer 2Adenocarcinoma Of Esophagus 2Vulvar Neoplasms 1

Interventions

Paclitaxel 328Carboplatin 323Bevacizumab 171Gemcitabine 106liposomal doxorubicin 104pembrolizumab 101Cyclophosphamide 96Topotecan 94olaparib 92Cisplatin 92niraparib 69Docetaxel 57Taxes 52Doxorubicin 51Drug Therapy 45fludarabine 40Filgrastim 39Nivolumab 37Magnetic Resonance Spectroscopy 34Surveys and Questionnaires 33Specimen Handling 33Etoposide 32Hyperthermic Intraperitoneal Chemotherapy 31Blood Specimen Collection 29Immunoglobulin G 27Disulfides 27Peripheral Blood Stem Cell Transplantation 26Cytoreduction Surgical Procedures 25Albumin-Bound Paclitaxel 25durvalumab 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Ovarian Neoplasms × trastuzumab deruxtecan × Clear all
NCT05417594 2026-06-02

CERTIS1

AstraZeneca

Phase 1/2 Recruiting
695 enrolled
BreastCNSGastrointestinalGenitourinaryGynecologic

Astrocytoma, Breast Neoplasms, Fallopian Tube Neoplasms, Glioma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT07124000 2026-06-01

DP-04

AstraZeneca

Recruiting
100 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Adenocarcinoma, Anus Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Melanoma, Mouth Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Testicular Neoplasms, Thyroid Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma

NCT06819007 2026-05-26

DO-01

Daiichi Sankyo

Phase 3 Recruiting
582 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT07340164 2026-04-20

TROY

Yonsei University

Phase 2 Recruiting
116 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡